Patients with signs of tumor hypoxia detected by advanced imaging such as 18F-FMISO PET or oxygen-sensitive biomarkers may be prioritized for evaluation for combined VEGF/HIF inhibition treatment and may be especially included in clinical trials based on criteria classification [16]. Here, VEGFA is linked to neoplasm.